Although most hepatitis C virus (HCV)-infected individuals develop chronic infection, about 25% of them are able to clear the virus spontaneously without any therapeutic intervention. The aim of the present study was to identify genes associated with spontaneous HCV clearance in a population of Iranian patients. We genotyped 110 single-nucleotide polymorphisms (SNPs) in 59 selected-candidate-genes in a cohort of 107 HCV-infected participants who spontaneously cleared the infection and 176 participants whose infection persisted. Three out of the 110 SNPs were found to be associated with HCV outcome (P-values o0.03). rs11506105 in EGFR (epidermal growth factor receptor gene), and rs11881222 and rs12979860 in IL28B (interferon-λ3 gene). Multivariate logistic regression of the three markers showed that the A/A genotypes in both rs11506105 (EFGR) and rs11881222 (IL28B), and the C/C genotype in rs12979860 (IL28B) are associated with HCV clearance (recessive model: odds ratio (OR) = 2.06, 95% confidence interval (95% CI) = 1.09-3.88, P = 0.025; OR = 2.09, 95% CI = 1.23-3.60, P = 0.007; and OR = 1.95, 95% CI = 1.15-3.35, P = 0.014 for rs11506105, rs12979860 and rs11881222, respectively). In conclusion, EGFR and IL28B SNPs are strong independent predictive markers of spontaneous viral clearance.
INTRODUCTION
Despite the recent advent of direct-acting antiviral agents, hepatitis C virus (HCV) infection remains of major public health concern, that is, with a global prevalence of 2%-3%, as many as 170 million people are presently infected worldwide. 1 Although most HCV-infected individuals develop chronic infection, which may lead to various complications including fibrosis, cirrhosis or hepatocellular carcinoma, however, about 25% of them recover spontaneously from infection. 2 In Iran, where the prevalence of HCV is reported to be about 0.5%, 3 the cost of HCV therapy, similar to many other low-and middle-income countries, is a significant burden on health-care system and withholding therapy on those who spontaneously clear the virus could be cost saving. On the basis of a population-based study of a large cohort (49 338) in Golestan province of Iran, the prevalence of chronic HCV infection based on 'recombinant immunoblot assay' was 0.5%, which declined to 0.31% when tested by PCR. 4 Among those who had acquired hepatitis C, the rate of spontaneous clearance was 38%. 4 Mechanisms of viral clearance are still only partially understood and, in addition to viral, behavioral and environmental factors, host genetics may have a considerable role in this process. As such, the specific identities of the host factors required for an effective immune response that successfully eliminates infection are largely unknown. Several studies have identified genetic polymorphisms in human leukocyte antigens, killer immunoglobulin-like receptors, chemokines, interleukins, interferonstimulated and virus cellular receptor genes that influence spontaneous HCV clearance. [5] [6] [7] [8] [9] [10] [11] However, to date, the best studied and strongest host factor associated with HCV clearance remains the IL28B gene encoding interferon-λ3 (IFNλ3). 12, 13 Information about further host genetic variations involved in clearance could lead to the development of more effective therapeutic and vaccine strategies.
The purpose of the present study was to identify host polymorphisms associated with spontaneous HCV clearance by a candidate gene approach targeting a total of 110 single-nucleotide polymorphisms (SNPs) in an Iranian patient population.
RESULTS
The demographic characteristics of the 107 spontaneous clearance individuals and 176 HCV persistence patients are presented in Table 1 . All patients were opium users with around 30% documented IV drug users. None had received prior blood transfusion(s) or reported to have engaged in extramarital sex. The age of infection is unknown but might have been concomitant to drug use, which has started for most individuals, during teenage years. There was a significant difference in the distribution of alanine aminotransferase levels (P = 1.84 × 10 − 6 ) between the two groups. The higher levels of alanine aminotransferase in the persistence group can be explained by liver inflammation resulting from ongoing HCV infection. 14 There was also a difference in the sex distribution (P = 0.002) in the clearance group and in the persistence group. In addition, we observed a significantly higher proportion (P = 0.002) of infected females in the clearance group (48.8%) as compared with infected males in the clearance group (28.9%), which confirms that HCV clearance is more likely to occur in females than in males. [15] [16] [17] One hundred and ten candidate SNPs in 59 genes or genomic locations were tested for association with spontaneous HCV clearance. No significant deviation (P o 0.02) from Hardy-Weinberg equilibrium was observed for any tested SNP in the two groups. Table 2 summarizes the resulting three SNPs distributed over two genes that were found to be more frequent in the clearance group than in the persistence group (for physical locations of these SNP within respective genes, see Supplementary Figure S1 ). The fact that two SNPs of IL28B-the strongest treatment response predictor to date 18 and one of the best studied genetic host factor also known to be involved in spontaneous viral clearance 12 -are associated with viral clearance validates the present cohort as to the host genetics of HCV infection. As shown in Table 2 , the A allele was significantly more frequent in clearance subjects than in persistence patients for both rs11506105 (epidermal growth factor receptor (EGFR)) and rs11881222 (IL28B) with frequencies of 49.5% versus 40.1% (odds ratio (OR) = 1.50, 95% confidence interval (95% CI) = 1.06-2.11, P = 0.021) and 80.8% versus 71.0% (OR = 1.69, 95% CI = 1.12-2.55, P = 0.012), respectively. In the case of the well-known rs12979860, the C allele was associated with spontaneous clearance with 79.0% versus 69.9% in the clearance versus persistence groups (OR = 1.78, 95% CI = 1.18-2.68, P = 0.006).
As sex 16 has been suggested to correlate with HCV persistence and as a significant difference in distribution of this parameter is observed between clearance and persistence subjects in the present cohort, the detected associations at EGFR and IL28B loci were assessed in univariate and multivariate logistic regression analyses including sex in addition to the geographic origin of the patients (Zahedan and Golestan) as co-variates (Table 3 ). In univariate analysis, for rs11506105 (EGFR) and rs11881222 (IL28B) the proportions of the A/A genotypes in clearance versus persistence groups were 25.2% versus 15.3% (recessive model: OR = 1.88, 95% CI = 1.03-3.44, P = 0.037) and 66.3% versus 51.1% (recessive model: OR = 1.86, 95% CI = 1.14-3.09, P = 0.014), respectively. The C/C genotype of rs12979860 (IL28B) was also significantly more frequent in subjects that cleared the virus than in patients with persistent infection (recessive model: 64.5% versus 48.3%, OR = 2.05, 95% CI = 1.25-3.40, P = 0.005). Importantly, after adjusting for sex and geographic origin of patients, the A/A genotypes of rs11506105 (EGFR) and rs11881222 (IL28B), and the C/C genotype of rs12979860 (IL28B) were still significantly associated with viral clearance (P = 0.025, P = 0.014 and P = 0.007 for rs11506105, rs11881222 and rs12979860, respectively), indicating that both EGFR and IL28B genotypes are predictive factors of virus clearance, independently of sex and geographic origin of the patients. Moreover, the favorable A/A (rs11506105 and rs11881222) and C/C (rs12979860) genotypes were confirmed by the additive model, which displayed multivariate P-values of 0.012 and 0.040 for rs11506105 and rs11881222, respectively, and 0.038 for rs12979860. In other words, individuals with non-favorable EGFR or IL28B genotypes (that is, rs11506105 GG or GA, rs11881222 GG or GA and rs12979860 TT or CT) are less likely to clear HCV infection compared with those who have favorable genotypes (that is, rs11506105 AA, rs11881222 AA and rs12979860 CC).
DISCUSSION
The present report demonstrates for the first time the association of IL28B polymorphisms with spontaneous HCV clearance in a group of Iranian HCV-infected individuals. Together with previous reports demonstrating associations of IL28B polymorphisms in multiple and ethnically diverse populations (for example, 12, 13, 19 ), the present result confirms that this gene is an important panpopulation host factor influencing HCV clearance. However, despite numerous association studies, the molecular mechanisms that link the genetic variants near the IL28B gene to spontaneous clearance of HCV remain largely unknown and still represent an important future challenge in understanding host-virus interactions. However, a few publications have reported functional roles of IL28B polymorphisms. For instance, a TT/-G polymorphism in the CpG region upstream of IL28B has been shown to induce the expression of both IL28B and IFN-γ-inducible protein 10 (IP-10). 20 More recently, McFarland et al. 21 reported that the functional rs4803217 polymorphim has an effect on AU-rich elementmediated decay of IL28B mRNA and on the binding of HCVinduced microRNAs during infection. The minor allele frequencies of the three markers are 26%, 25% and 45% for rs12979860, rs11881222 and rs11506105, respectively. Interestingly, these minor allele frequency values are comprised between those in the European population (31%, 29% and 45%) and those in the Asian population (8%, 8% and 35%) ( Supplementary Table S1 ).
Most importantly, this study brings to light that a polymorphism in EGFR has a prominent role in HCV clearance. EGFR is a receptor tyrosine kinase, which regulates key processes such as cell proliferation, survival, differentiation during development, tissue homeostasis and tumorigenesis. 22 It has recently been demonstrated that EGFR is a host factor participating in the viral entry, 23 a complex multistep process involving interaction of HCV E1/E2 envelope glycoproteins with multiple cell cofactors such as glycosaminoglycans, low-density lipoprotein receptor, SR-B1, CD81, claudin-1, occludin and EphA2. (ref. 24) EGFR does not directly interact with the virus particle, but it promotes the formation of the CD81-CLDN1 complex, which is required for HCV entry. 23 One can hypothesize that the genotype of rs11506105 influence-by a yet unknown mechanism-the action of EGFR on CLDN1 and/or CD81 trafficking, which are necessary to form receptor complexes for efficient HCV entry. It is important to notice that the EGFR inhibitor Erlotinib (Tarceva, Roche, Basel, Switzerland), targeting EGFR and CD81-CLDN1 co-receptor associations and already licensed for treatment of lung cancer, 25 has reached clinical development to determine the safety and efficacy in patients with HCV infection (ClinicalTrials.gov identifier NCT01835938: http://clinicaltrials.gov/show/NCT01835938).
In conclusion, besides confirming the critical role of IL28B in spontaneous viral clearance, the present report shows for the first time an association of an EGFR polymorphism with HCV clearance, bringing valuable information in the context of development of new therapeutic approaches for HCV-infected individuals.
PATIENTS AND METHODS

Study population
The study group consisted of 176 chronically infected participants (HCV persistence group) and 107 individuals who recovered spontaneously from infection (HCV clearance group). The participants were patients participating in the Golestan cohort study including three main districts of Golestan province 26 and patients consulting an addiction treatment center or a needle and syringe exchange center in Zahedan. The persistence group was composed of 153 participants from Golestan province and 23 patients from Zahedan. All subjects of this group had chronic HCV infection as proven by the presence of anti-HCV antibodies tested by enzyme-linked immunorsorbent assay (Diapro, Milano, Italy) and recombinant immunoblot assay (MT Company, Berlin, Germany), as well as the presence of HCV RNA tested by reverse-transcription PCR (STRPTM Hepatitis C Virus Detection Kit, CinnaGen, Tehran, Iran) in serum before any HCV treatment. Individuals of the clearance group were enrolled from Golestan province (n = 95) and Zahedan (n = 12), and were characterized by the presence of anti-HCV antibodies (confirmed by recombinant immunoblot assay) and undetectable HCV RNA concentrations in serum without any HCV therapy as determined by Cobas Taqman assay (o 18.5 IU ml − 1 ). Informed consent for genetic testing was obtained from all participants and the study was 
Selection of SNPs and genotyping
Fifty nine candidate genes or genomic locations that were either known to be involved in HCV-host interactions or have previously been associated with HCV clearance, susceptibility to infection, treatment response, disease course or HCV RNA replication were selected for this study. For genes that had never been tested in genetic association studies, we used HapMap data to select candidate SNPs. SNPs were filtered to those with a minor allele frequency 40.05 and pairwise tags were chosen with a pairwise linkage disequilibrium estimates (r 2 ) threshold of 0.8. The resulting 110 SNPs are presented in Table 4 . A more detailed list of selected SNPs including bibliographic references and functional categories are provided in Supplementary Table S2 . Before SNP genotyping, genomic DNA was extracted from 0.5 ml peripheral blood using a robotic workstation (QiaSymphony, Qiagen, Hilden, Germany) and following the manufacturer's instructions. The range of the absorbance ratio A 260nm /A 280nm was 1.7-1.9 for all samples and extraction yields varied between 5 and 40 μg of DNA per 0.5 ml of whole blood. SNP genotyping was performed using the Open Array Real-Time PCR System (Life Technologies, Foster City, CA, USA), using arrays synthesized by Life Technologies and following the manufacturer's instructions. Briefly, after normalization of sample concentrations to 5 ng μl − 1 , 5 μl of DNA were loaded on the Open Array plates with the Accufill robot (Life Technologies). One non-template control was spotted after every 32 samples. Cycling was performed using a flat-block GeneAmp PCR System 9700 (Life Technologies) and arrays were finally scanned with the Open Array Imager. The loading of the arrays was checked using the ROX image (passive dye) and the fluorescence signal strength was assessed using the VIC and FAM images with the software tool ImageJ (http://imagej.nih.gov/ij/). Genotypes were determined using OpenArray SNP Genotyping Analysis Software v1.0.5. All tested SNPs had a genotyping success rate above 95%.
Statistical analysis
Distributions of genotypes between the clearance and the persistence groups was performed by the χ 2 -test. ORs and 9595% CIs were calculated for the tested alleles in the clearance versus persistence groups. Because of the exploratory nature of the study, P-values were not adjusted for multiple testing. P-values below 0.05 were considered statistically significant. PLINK 27 was used to test for Hardy-Weinberg equilibrium. Statistical differences of subject characteristics such as age or sex between groups were evaluated using the χ 2 -test for qualitative variables and t-test or analysis of variance for quantitative variables. Univariate and multivariate logistic regression analyses were performed using SPSS for Windows (release 12.0.1; SPSS, New York, NY, USA). Results of logistic regression were reported in terms of OR with 95% CI. Power calculations were determined using the statistical program Quanto (http://biostats.usc. edu/software.html). Assuming a population-wide HCV clearance rate of 25%, this study had 80% power to detect an associated SNP with a frequency of 25% and a relative risk of 43.65.
